{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:40:02Z","timestamp":1781523602274,"version":"3.54.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Janssen"},{"name":"Health\u223cHolland, Top Sector Life Sciences & Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To identify novel serum proteins involved in the pathogenesis of PsA as compared with healthy controls, psoriasis (Pso) and AS, and to explore which proteins best correlated to major clinical features of the disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A high-throughput serum biomarker platform (Olink) was used to assess the level of 951 unique proteins in serum of patients with PsA (n\u2009=\u200920), Pso (n\u2009=\u200918) and AS (n\u2009=\u200919), as well as healthy controls (HC, n\u2009=\u200920). Pso and PsA were matched for Psoriasis Area and Severity Index (PASI) and other clinical parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found 68 differentially expressed proteins (DEPs) in PsA as compared with HC. Of those DEPs, 48 proteins (71%) were also dysregulated in Pso and\/or AS. Strikingly, there were no DEPs when comparing PsA with Pso directly. On the contrary, hierarchical cluster analysis and multidimensional scaling revealed that HC clustered distinctly from all patients, and that PsA and Pso grouped together. The number of swollen joints had the strongest positive correlation to ICAM-1 (r\u2009=\u20090.81, P\u2009&amp;lt;\u20090.001) and CCL18 (0.76, P\u2009&amp;lt;\u20090.001). PASI score was best correlated to PI3 (r\u2009=\u20090.54, P\u2009&amp;lt;\u20090.001) and IL-17 receptor A (r\u2009=\u2009\u20130.51, P\u2009&amp;lt;\u20090.01). There were more proteins correlated to PASI score when analysing Pso and PsA patients separately, as compared with analysing Pso and PsA patients pooled together.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>PsA and Pso patients share a serum proteomic signature, which supports the concept of a single psoriatic spectrum of disease. Future studies should target skin and synovial tissues to uncover differences in local factors driving arthritis development in Pso.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa405","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:18:20Z","timestamp":1592392700000},"page":"751-761","source":"Crossref","is-referenced-by-count":26,"title":["Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7367-0185","authenticated-orcid":false,"given":"Emmerik","family":"Leijten","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyang","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Pouw","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"van Kempen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Olde Nordkamp","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Balak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Tekstra","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Mu\u00f1oz-El\u00edas","sequence":"additional","affiliation":[{"name":"Immunology Biomarkers, Janssen Research & Development LLC, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"DePrimo","sequence":"additional","affiliation":[{"name":"Immunology Biomarkers, Janssen Research & Development LLC, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Drylewicz","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aridaman","family":"Pandit","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Boes","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, Utrecht, The Netherlands"},{"name":"Department of Pediatrics, UMC Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Radstake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands"},{"name":"Center for Translational Immunology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2021020119155336900_keaa405-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2021020119155336900_keaa405-B2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","article-title":"The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies","volume":"78","author":"Kavanaugh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021020119155336900_keaa405-B3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","article-title":"Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"key":"2021020119155336900_keaa405-B4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021020119155336900_keaa405-B5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3899\/jrheum.170143","article-title":"Basic and translational science: a report from the GRAPPA 2016 Annual Meeting","volume":"44","author":"Krueger","year":"2017","journal-title":"J Rheumatol"},{"key":"2021020119155336900_keaa405-B6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2017.96","article-title":"Why location matters\u2014site-specific factors in rheumatic diseases","volume":"13","author":"Ospelt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2021020119155336900_keaa405-B7","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"2021020119155336900_keaa405-B8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2340\/00015555-2385","article-title":"Psoriasis and psoriatic arthritis: flip sides of the coin?","volume":"96","author":"Boehncke","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2021020119155336900_keaa405-B9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","article-title":"Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data","volume":"16","author":"Sakkas","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2021020119155336900_keaa405-B10","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun"},{"key":"2021020119155336900_keaa405-B11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am J Hum Genet"},{"key":"2021020119155336900_keaa405-B12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/jid.2014.414","article-title":"Gene expression differences between psoriasis patients with and without inflammatory arthritis","volume":"135","author":"Pollock","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2021020119155336900_keaa405-B13","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.39800","article-title":"Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis","volume":"68","author":"Abji","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021020119155336900_keaa405-B14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ced.12251","article-title":"Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis","volume":"39","author":"Capsoni","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"2021020119155336900_keaa405-B15","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021020119155336900_keaa405-B16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/art.40830","article-title":"Identification of novel autoantibodies associated with psoriatic arthritis","volume":"71","author":"Yuan","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021020119155336900_keaa405-B17","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front Immunol 2018"},{"key":"2021020119155336900_keaa405-B18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/rheumatology\/keq105","article-title":"Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis","volume":"49","author":"Chandran","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119155336900_keaa405-B19","first-page":"120","article-title":"S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?","volume":"27","author":"Alenius","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2021020119155336900_keaa405-B20","doi-asserted-by":"crossref","first-page":"e46740","DOI":"10.1371\/journal.pone.0046740","article-title":"Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions","volume":"7","author":"Xue","year":"2012","journal-title":"PLoS One"},{"key":"2021020119155336900_keaa405-B21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000471798","article-title":"New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology"},{"key":"2021020119155336900_keaa405-B22","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar3123","article-title":"Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion","volume":"12","author":"Dalbeth","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2021020119155336900_keaa405-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/194535","article-title":"The assessment of selected bone and cartilage biomarkers in psoriatic patients from Poland","volume":"2015","author":"Bartosi\u0144ska","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2021020119155336900_keaa405-B24","doi-asserted-by":"crossref","first-page":"e0153094","DOI":"10.1371\/journal.pone.0153094","article-title":"Effect of vitamin D on peripheral blood mononuclear cells from patients with psoriasis vulgaris and psoriatic arthritis","volume":"11","author":"Cubillos","year":"2016","journal-title":"PLoS One"},{"key":"2021020119155336900_keaa405-B25","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1111\/ijd.13159","article-title":"Serum level of receptor activator of nuclear factor kappa-B ligand in patients with psoriasis","volume":"55","author":"Amin","year":"2016","journal-title":"Int J Dermatol"},{"key":"2021020119155336900_keaa405-B26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1346-8138.13061","article-title":"Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis","volume":"43","author":"Kim","year":"2016","journal-title":"J Dermatol"},{"key":"2021020119155336900_keaa405-B27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ced.12670","article-title":"Serum IL-33 levels are increased in patients with psoriasis","volume":"41","author":"Mitsui","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2021020119155336900_keaa405-B28","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"key":"2021020119155336900_keaa405-B29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2017.08.040","article-title":"Reduction of inflammatory and cardiovascular proteins in the blood of patients with psoriasis: differential responses between tofacitinib and etanercept after 4 weeks of treatment","volume":"138","author":"Kim","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2021020119155336900_keaa405-B30","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021020119155336900_keaa405-B31","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2021020119155336900_keaa405-B32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1471-2164-9-488","article-title":"BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams","volume":"9","author":"Hulsen","year":"2008","journal-title":"BMC Genomics"},{"key":"2021020119155336900_keaa405-B33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/ard.53.7.450","article-title":"Immunohistochemical markers for arthritis in psoriasis","volume":"53","author":"Veale","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"2021020119155336900_keaa405-B34","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1038\/s41598-017-07975-2","article-title":"Signs of innate immune activation and premature immunosenescence in psoriasis patients","volume":"7","author":"\u0160ahmatova","year":"2017","journal-title":"Sci Rep"},{"key":"2021020119155336900_keaa405-B35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/art.1780360705","article-title":"Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis","volume":"36","author":"Veale","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2021020119155336900_keaa405-B36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2133.1995.tb08621.x","article-title":"Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin","volume":"132","author":"Veale","year":"1995","journal-title":"Br J Dermatol"},{"key":"2021020119155336900_keaa405-B37","doi-asserted-by":"crossref","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2021020119155336900_keaa405-B38","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.23507","article-title":"Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis","volume":"58","author":"Viguier","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021020119155336900_keaa405-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom8010001","article-title":"Emerging roles for VEGF-D in human disease","volume":"8","author":"Stacker","year":"2018","journal-title":"Biomolecules"},{"key":"2021020119155336900_keaa405-B40","first-page":"345","article-title":"Angiogenesis in inflammatory arthritis","volume":"5","author":"Balogh","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"2021020119155336900_keaa405-B41","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","article-title":"Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis","volume":"7","author":"Kruithof","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2021020119155336900_keaa405-B42","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1136\/annrheumdis-2014-205216","article-title":"Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021020119155336900_keaa405-B43","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/ard.2006.066084","article-title":"Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis","volume":"66","author":"Lieshout","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021020119155336900_keaa405-B44","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1007\/s00018-019-03173-7","article-title":"Functions of \u201cA disintegrin and metalloproteases (ADAMs)\u201d in the mammalian nervous system","volume":"76","author":"Hsia","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"2021020119155336900_keaa405-B45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cas.12895","article-title":"ADAM23 is downregulated in side population and suppresses lung metastasis of lung carcinoma cells","volume":"107","author":"Ota","year":"2016","journal-title":"Cancer Sci"},{"key":"2021020119155336900_keaa405-B46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1267\/ahc.14027","article-title":"Notch signaling may be involved in the abnormal differentiation of epidermal keratinocytes in psoriasis","volume":"47","author":"Ota","year":"2014","journal-title":"Acta Histochem Cytochem"},{"key":"2021020119155336900_keaa405-B47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2249.2010.04310.x","article-title":"Engagement of activated Notch signalling in collagen II-specific T helper type 1 (Th1)- and Th17-type expansion involving Notch3 and Delta-like1","volume":"164","author":"Jiao","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"2021020119155336900_keaa405-B48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2021020119155336900_keaa405-B49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fmed.2019.00144","article-title":"Major challenges in rheumatology: will we ever treat smarter, instead of just harder","volume":"6","author":"Rom\u00e3o","year":"2019","journal-title":"Front Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/751\/36167961\/keaa405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/751\/36167961\/keaa405.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T04:22:12Z","timestamp":1612326132000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/2\/751\/5892431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa405","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,8,13]]}}}